About maralixibat
IBAT inhibitor
Used for
- Treats itching associated with Alagille syndrome in adults and children.
- Treats itching associated with progressive familial intrahepatic cholestasis in adults and children.
Usual adult dose
Alagille syndrome: start 190 micrograms/kg twice daily; increase after one week to 380 micrograms/kg twice daily. Progressive familial intrahepatic cholestasis: start 285 micrograms/kg twice daily; increase after one week to 570 micrograms/kg twice daily.
Usual dose in children
Weight-based dosing is used for children; dose and maximum depend on age, weight, and condition.
Common side effects
- Diarrhea
- Abdominal pain
- Nausea or vomiting
- Fat-soluble vitamin deficiencies
Important warnings
- Monitor liver tests and fat-soluble vitamin levels.
- Severe diarrhea can cause dehydration; persistent symptoms may require dose adjustment.
- May affect absorption of other medicines; separate certain medicines as directed.
- Not recommended in severe liver impairment or complete biliary obstruction.
Pregnancy
Human pregnancy information is limited. Use only when a clinician determines expected benefits outweigh potential risks.
Breastfeeding
It is unknown whether maralixibat passes into breast milk; discuss risks and benefits with a clinician.
Interactions
- Bile acid sequestrants can reduce absorption; separate administration by at least four hours.
- May reduce absorption of fat-soluble vitamins; monitor vitamin levels.
- May alter absorption of other oral medicines; review timing with a pharmacist.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.